Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / Inhibitex Inc.
2012 · Acquisition/Merger · $2.5B · Complete
Announcement Sentiment
75
Strongly positive
Outcome Score
8
Did not work — the deal failed to deliver.
BMS acquired Inhibitex for $2.5B for hepatitis C drug development.
Did it work? Outcome assessment
BMS / Inhibitex: Failed to Achieve (Score: 26/100)
Strategic verdict
Failed to Achieve
Assessment window: 5yr post-close.
Key facts
- Announced Jan 07, 2012
- Closed Feb 13, 2012
- Deal value $2.5B
- Deal type Acquisition/Merger
- Therapeutic area Infectious Disease
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals